Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited is a leading research-driven, integrated pharmaceutical enterprise specialising in the development and manufacturing of generic formulations across diverse therapeutic areas, including cardiology, anti-infective, gynaecology, ophthalmology, oncology and chronic therapies

Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited. The company is engaged in pharmaceuticals business. As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010.

In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.

In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange.

During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA.

During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA.

During 2014, the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.'.

During 2015, the company's associate signs exclusive agreement with Novartis. During the year, the company launched Aripiprazole on Day-1. Also during the year, the company transitioned to own marketing in the US.

In 2016, the company formed 60:40 joint venture with Orbicular v